Latest Breaking News On - Clinical oncology annual meeting - Page 1 : comparemela.com

Putting Quality of Life into Perspective During CML Treatment

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Most Patients With CML Can Continue Their Normal Lifestyle During Treatment

Organizations Can Help Patients with CML Face the 'Long Treatment Journey'

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center